Ono Pharmaceutical Co (TSE:4528) LT-Debt-to-Total-Asset: 0.08 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4528 Ono Pharmaceutical Co Ltd TSE:4528
89 GF Score
Price 円2,432.50
GF Value 円2,239.11
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Ono Pharmaceutical Co LT-Debt-to-Total-Asset?

Ono Pharmaceutical Co TSE:4528 +1.33% 89 LT-Debt-to-Total-Asset is 0.08 as of Mar. 2026. GuruFocus rates TSE:4528 with a GF Score™ of 89/100 and a GF Value™ of 円2,239.11 (Fairly Valued). The stock has 4 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Ono Pharmaceutical Co's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.08.

Ono Pharmaceutical Co's long-term debt to total assets ratio declined from Mar. 2025 (0.11) to Mar. 2026 (0.08). It may suggest that Ono Pharmaceutical Co is progressively becoming less dependent on debt to grow their business.

Ono Pharmaceutical Co  (TSE:4528) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Ono Pharmaceutical Co LT-Debt-to-Total-Asset Related Terms

Ono Pharmaceutical Co LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Ono Pharmaceutical Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ono Pharmaceutical Co LT-Debt-to-Total-Asset Chart

Ono Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.01 0.01 0.11 0.08

Ono Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.11 0.10 0.09 0.08 0.08
TSE:4528
89GF Score
Ono Pharmaceutical Co Ltd TSE:4528
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ono Pharmaceutical Co LT-Debt-to-Total-Asset Calculation

Ono Pharmaceutical Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (A: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (A: Mar. 2026 )/Total Assets (A: Mar. 2026 )
=82468/1106515
=0.07

Ono Pharmaceutical Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=82468/1106515
=0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.08 mean?
Ono Pharmaceutical Co (TSE:4528) has a LT-Debt-to-Total-Asset of 0.08 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Ono Pharmaceutical Co and its competitors.
Is Ono Pharmaceutical Co's LT-Debt-to-Total-Asset too high?
Ono Pharmaceutical Co's current LT-Debt-to-Total-Asset is 0.08. Overall, Ono Pharmaceutical Co has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ono Pharmaceutical Co's LT-Debt-to-Total-Asset compare to LLY and JNJ?
Ono Pharmaceutical Co's LT-Debt-to-Total-Asset of 0.08 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?
A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Ono Pharmaceutical Co and its competitors. Ono Pharmaceutical Co's current LT-Debt-to-Total-Asset is 0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ono Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Ono Pharmaceutical Co (TSE:4528) is currently considered Fairly Valued. The stock's GF Value™ is 円2,239.11, compared to a current price of 円2,432.50 — trading 8.6% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.08. Ono Pharmaceutical Co's overall GF Score™ is 89/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Ono Pharmaceutical Co (TSE:4528), the current LT-Debt-to-Total-Asset is 0.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ono Pharmaceutical Co (TSE:4528) Overvalued in 2026?

Based on GuruFocus' analysis, Ono Pharmaceutical Co stock appears to be overvalued. The current stock price of 円2,432.50 is trading 8.6% above its estimated GF Value™ of 円2,239.11. GuruFocus considers Ono Pharmaceutical Co to be Fairly Valued.

Key valuation signals for TSE:4528:

  • LT-Debt-to-Total-Asset: 0.08
  • GF Value™: 円2,239.11 vs. price of 円2,432.50 (8.6% above fair value)
  • GF Score™: 89/100 with 4 warning signs

No single metric tells the full story. See the TSE:4528 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ono Pharmaceutical Co Business Description

Other Exchanges OPHLY:USAON4:Germany
Address 1-8-2 Kyutarocho, Chuo-ku, Osaka, JPN, 541-8564
Ono Pharmaceutical Co Ltd is a drug manufacturer with a focus on drug discovery in areas of unmet medical needs. The vast majority of the company's revenue is derived from its circulatory and respiratory drugs, followed by its metabolic drugs and vitamins. The company also reports revenue derived from royalties. The bulk of the company's sales is generated in Japan, followed by the rest of Asia and Europe.
89GF Score

Get the complete analysis for TSE:4528

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円2,432.50
Price
円2,239.11
GF Value